Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 EYLEA achieves primary endpoint in BRVO Study | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

EYLEA achieves primary endpoint in BRVO Study

53% of patients experience improved vision

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Regeneron Pharmaceuticals achieved positive results for EYLEA (aflibercept) Injection from the Phase III VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). In the trial, 53% of patients who received EYLEA 2 milligram every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of patients who received laser, a standard-of-care treatment.
 
The incidence of serious adverse events (SAE) was 9.9% in the EYLEA group and 9.8% in the laser group. The most common ocular adverse events in the EYLEA treated patients were conjunctival hemorrhage and eye pain.  
 
EYLEA is currently approved for the treatment of neovascular (wet) Age-related Macular Degeneration (AMD) and Macular Edema following Central Retinal Vein Occlusion (CRVO).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters